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Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive loss of cognitive functions. Today the
diagnosis of AD relies on clinical evaluations and is only late in the disease. Biomarkers for early detection of the underlying
neuropathological changes are still lacking and the biochemical pathways leading to the disease are still not completely
understood. The aim of this study was to identify the metabolic changes resulting from the disease phenotype by a
thorough and systematic metabolite profiling approach. For this purpose CSF samples from 79 AD patients and 51 healthy
controls were analyzed by gas and liquid chromatography-tandem mass spectrometry (GC-MS and LC-MS/MS) in
conjunction with univariate and multivariate statistical analyses. In total 343 different analytes have been identified.
Significant changes in the metabolite profile of AD patients compared to healthy controls have been identified. Increased
cortisol levels seemed to be related to the progression of AD and have been detected in more severe forms of AD. Increased
cysteine associated with decreased uridine was the best paired combination to identify light AD (MMSE.22) with specificity
and sensitivity above 75%. In this group of patients, sensitivity and specificity above 80% were obtained for several
combinations of three to five metabolites, including cortisol and various amino acids, in addition to cysteine and uridine.
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Introduction
Alzheimer’s disease (AD) is a progressive and devastating
neurodegenerative disorder of the brain characterized by loss of
neurons and synapses, particularly in regions related to memory
and cognition. AD is the most common form of dementia and its
prevalence increases dramatically with age, from1% at the age of
around 60 and up to 30% at the age of 85 or older [1].
Two main brain cortical lesions characterize AD: the accumu-
lation of abnormally phosphorylated tau protein into paired helical
filaments, known as neurofibrillary tangles (NFTs) within the
neuronal cell and accumulation of beta amyloid outside the
neurons in form of amyloid plaques and in the wall of cerebral
blood vessels [2].
Diagnosis of AD relies on a combination of neuropsychological
testing and the exclusion of other neurological, psychiatric or
systemic diseases by the means of physical, neurological and
laboratory examinations. The most often used neuropsychological
criteria to diagnose AD were developed by the National Institute of
Neurologic and Communicative Disorders and Stroke (NINCDS)
and the Alzheimer’s diseases and Related Disorders Association
(ADRDA) workgroup in 1984 [3]. Because the clinical diagnosis of
AD happens at a late stage of the disease, i.e. several years after the
onset of the neuropathological alterations, there was an urgent need
to revise these criteria in order to characterize the disease at a pre-
dementia stage. It was proposed to take into account neuroimaging
biomarkers and cerebrospinal fluid (CSF) analysis of amyloid beta
ortau proteinsinadditiontothepresenceofdeteriorationinspecific
cognitive domains such as episodic memory [4]. In vivo imaging of
amyloid deposits in the brain using specific PET ligands have made
strong progress in the last few years and provide valuable tools for
diagnosis, patient stratification and monitoring disease progression
[5,6]. Main drawbacks of PET are its high cost and restriction to
highly specialized centers. Today, molecular CSF analyses appear
as more promising, simpler and less expensive than imaging
methods. The currently best CSF candidates are the amyloid-b (1–
42) fragment and the Tau protein. Combinations of these markers
reach sensitivity of about 90 to 95% and specificity about 85% (for
review see [7]). However, using these CSF markers there is still huge
overlap with other forms of dementia. and the capacity of these
parameters to identify the therapeutic efficacy of new disease-
modifying treatments has not yet been proven [8]. Taking into
account the multifactorial nature of AD, it is likely that the same
clinical manifestations are underlain by different neuropathological
mechanisms. Thus, combination of several biological markers
acting at different physiological levels can bring complementary
information for diagnostics of various disease phenotypes and for
monitoring biological drug effects.
High-density ‘‘Metabonomics/Metabolomics’’ approach offers
the prospect of efficiently distinguishing individuals with particular
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biofluids. Emerging specific analytical technologies, including
nuclear magnetic resonance (NMR) and liquid chromatography-
tandem mass spectrometry (LC-MS) are particularly relevant to
produce unbiased metabolic signatures of biofluids and tissues (for
a review see [9]). In particular for CSF the situation is especially
favorable since many endogenous metabolites in this compartment
are known and have spectroscopically been assigned [10].
Here we show the metabolic profile in human CSF samples of
AD patients and age-matched healthy controls. This approach
attempts to identify candidates for biomarkers traced to particular
metabolites or pathways specific for AD or the underlying
neurodegenerative process and is used as a starting point for
further validation in independent sample sets.
Materials and Methods
Participants and ethics
Subjects of both sexes aged of 40 years or above were recruited
in five different clinical centres in Europe: One in Germany, one
in France, one in Switzerland, and two in Sweden, after approval
of the protocol by the ethics committee of the corresponding
countries: University Clinic Munich, CCPPRB Alsace I Stras-
bourg, Ethikommission beider Basel, University Clinic Huddinge
and Uppsala. All procedures were conducted according to the
principles expressed in the declaration of Helsinki and all subjects
gave their written informed consent. In case patients were
considered not to have the capacity, inform consent was given
by relatives.
Diagnosis of AD was made according to the NINCDS-ADRDA
and DSM IV criteria. The Hachinski ischemia scale was used to
exclude dementia of the vascular type. Controls were age-matched
cognitively normal persons. For all subjects, the following drugs
were prohibited: anticoagulants or anti-inflammatory (COX-2
inhibitors) for at least 3 months, symptomatic treatment for
cognitive disorders within 30 days, treatments for depression,
schizophrenia or anxiety if not stabilized for at least 30 days.
Details on demographic and clinical characteristics are given in
Table 1.
Study procedures
A MRI examination or PET scan was performed in patients if
these examinations were not realized within the last 12 months.
CSF samples were taken according to standard procedures in both
patients and healthy subjects for metabolite profiling and
determination of the concentrations of Abeta42 and tau protein.
Samples were collected using the same type of tubes, labeled by
Roche and shipped to the different clinical centers.
Metabolite Profiling. Three types of mass spectrometry
analysis were applied to all samples: GC-MS (gas chromatography-
mass spectrometry) and LC-MS/MS (liquid chromatography-MS/
MS) were used for broad profiling, as described elsewhere [11]. SPE-
LC-MS/MS(solidphaseextraction-LC-MS/MS) wasapplied forthe
determination of catecholamine and steroid levels. Proteins were
removed from CSF samples by precipitation. Subsequently polar and
non-polar fractions were separated for both GC-MS and LC-MS/
MS analysis by adding water and a mixture of ethanol and dichloro-
methane. For GC-MS analysis, the non-polar fraction was treated
with methanol under acidic conditions to yield the fatty acid methyl
esters derived from both free fatty acids and hydrolyzed complex
lipids. The non-polar and polar fractions were further derivatized
with O-methyl-hydroxyamine hydrochloride and pyridine to convert
oxo-groups to O-methyl-oximes and subsequently with a silylating
agent before analysis [12]. For LC-MS analysis, both fractions were
reconstituted in appropriate solvent mixtures. HPLC was performed
by gradient elution using methanol/water/formic acid on reversed
phase separation columns. Mass spectrometric detection technology
was applied which allows target and high sensitivity MRM (multiple
reaction monitoring) profiling in parallel to a full screen analysis
(Patent: WO2003073464). For GC-MS and LC-MS/MS profiling,
data were normalized to the median of reference samples which were
derived from a pool formed from aliquots ofallsamplesto account for
inter- and intra-instrumental variation. Steroids, catecholamines and
their metabolites were measured by online SPE-LC-MS/MS [13].
Absolute quantification was performed by means of stable isotope-
labelled standards.
Statistical analysis
Simple (t-test) and multi-factor ANOVA models capturing the
factors gender and age in addition to disease status were estimated
for log10-transformed relative concentrations (Ratios) of all semi-
quantitative SQ-metabolites (see ‘‘Types, number and quality of
analytes measured’’) and absolute CSF concentrations of (p-)Tau
and amyloid beta proteins (Analysis conducted by the statistics
software R) [14]. ANOVA models were applied to correct
metabolic data for age and gender and to select metabolites with
high diagnostic potential. The resulting gender- and age-corrected
metabolites were combined (pairs to quintets) and the combinations
examined by binary disease status classification using penalised
logistic regression (PLR) [15] and receiver operating characteristics
(ROC) analysis [16]. Metabolite combinations were evaluated by
area under curve (AUC) values of their corresponding PLR
classifier. AUC values indicate the extent to which samples can be
correctly classified without specifying a classification threshold.
Multivariate statistics is a form of statistics encompassing the
simultaneous observation and analysis of more than one statistical
variable. Multivariate statistics was performed by using Simca P+
software (Umetrics, Umea, Sweden). The data analysis included
PCA (principal component analysis) and OPLS-DA (orthogonal
projections to latent structures-discriminant analysis). Prior to
PCA and OPLS-DA, data were scaled to unit variance introducing
a common scale for all metabolites independent of their absolute
amount of variance. Thereby, the resulting models obtained
robustness, i.e. they could not be dominated by a single or few
Table 1. Characteristic of study and participants for all
centers and core centers.
CHARACTERISTIC







2 53 26 51
Participant (core)
3 47 24 30
Gender M/F (all) 23/30 12/14 24/27
Gender M/F (core) 21/26 11/13 13/17
Age in years (all) 69.7 (69.5) 69.6 (610.1) 63.1 (67.7)
Age in years (core) 68.5 (69.3) 68.2 (69.3) 65.1 (68.8)
MMSE (all) 25.8 (61.7) 19.7 (62.6) na
MMSE (core) 25.8 (61.6) 19.7 (62.6) na
1sample volume: 500 ml CSF; for 4 patients with MMSE.22 ,500 ml were
available leading to incomplete data sets.
2‘‘all’’ means from five different clinical centers in Europe, two of them
providing only samples from controls (21) and AD (8), resp.
3‘‘core’’ includes only three from five centers which provided both control and
AD samples.
doi:10.1371/journal.pone.0031501.t001
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multivariate analysis method used for the detection of trends,
patterns and groupings among samples and variables. In addition,
it is also useful for the detection of biological outliers (=deviating
samples that are extremely different from the rest of the data set).
Therefore, PCA was used both at the level of quality control as
well as to obtain an unbiased overview of the metabolite profiling
dataset. In order to focus on differences between specific sample
groups, i.e. AD patients and healthy controls, OPLS-DA as a
supervised multivariate approach was used for prediction and
classification purposes. Hereby, specific prior knowledge is
incorporated by assigning samples to the respective classes. The
principle of OPLS-DA is to well approximate metabolic data and
class assignments, and at the same time to maximize their
correlation. Abeta 42 and tau/pTau were measured using
commercially available ELISA assays (Innogenetics, Belgium).
Results
Study and sample details
Two of the participating centers provided only samples from
healthy controls (n=21) and from AD patients (n=8), respective-
ly. The samples were collected at various time points between
2000 and 2005. Disease samples originated from AD patients with
varying degree of dementia as indicated by different scores from
the MMSE: light or mild AD (MMSE.22), or strong AD (MMSE
14–22). In total 79 CSF samples from AD patients and 51 CSF
samples from healthy subjects were analyzed. In addition the
concentration of the AD protein biomarkers amyloid beta 42, p-
Tau 181, and Tau were known for a subset of 43 samples, 19 of
which were from the control group, 17 belonged to the group of
light AD patients and 7 to the group of strong AD patients. The
distribution of the samples over the various patient groups is
summarized in Table 1.
Types, number and quality of analytes measured
An overview of the various analytical methods that were applied
for metabolite profiling of the CSF samples is schematically shown
in Figure 1. In order to gain maximum information, the polar
phase was subjected to different liquid chromatographic separa-
tion conditions as well as different ionization techniques for mass
spectrometric detection. In LC-MS/MS, a targeted profiling
technology was applied which allowed for high sensitivity Multiple
Reaction Monitoring (MRM) in parallel to untargeted full screen
profile analysis [11]. For the lipid fraction, tandem-MS experi-
ments made the observation of specific transitions possible that are
typical for certain lipid classes, especially phospholipids.
A list of all structurally assigned metabolites with their relative
change in the different groups is provided in Table S1.
In addition, a number of catecholamines and steroids that are
discussed in the context of AD and are present in CSF at very low
concentration levels (ng/ml) were analyzed (Table S2). These
analytes are hardly accessible with standard metabolite profiling
techniques. In order to get access, two on-line SPE-LC-MS/MS
were applied that allow for absolute quantification by use of
calibration standards. The experimental details of all the
separation and metabolite profiling techniques have been
documented in the previous section.
Statistical analysis is confined to 343 analytes which were
measured at concentrations being well above the limit of
quantification (LOQ) allowing SQ analysis. This is to make sure
that results based on SQ-analyte data are analytically reliable, i.e.
SQ-analytes are used to detect quantifiable differentiating features
between sample collectives. The group of SQ analytes comprised
80 known metabolites, i.e. structurally assigned (target) metabo-
lites, including 15 hormones/neurotransmitters (steroids, catechol-
amines and related) for which absolute quantification was
provided, and 260 known-unknowns. The latter are those found
in each sample with a defined retention time and mass spectrum
but the identification via chromatopraphic comparison or isolation
and structural elucidation has not yet been accomplished.
Typically the number of known-unknowns is very much higher
in biological samples than the knowns.
Univariate statistical evaluation
Univariate statistical t-test analysis of the SQ-analytes was
carried out for females and males. The results are shown in table 2
for two different significance thresholds depending on gender and
disease status: light AD with MMSE.22, strong AD with MMSE
14–22 and all AD patients. Detailed statistical analysis data for all
structurally assigned metabolites is shown in Table S1.
The univariatestatisticalanalysisrevealed thatfemaleAD patients
show a higher number of significant metabolic changes than male
AD patientscompared tohealthy controls. This observation isinline
with larger sample groups yielding higher test power and larger age-
imbalance for females than for males. Furthermore, females
diagnosed with light AD (MMSE.22) exhibit more alterations than
those diagnosed with advanced AD (MMSE 14–22).
The intersection of significantly changed analytes (p,0.05;
ADall vs. controls) for females (29) and males (27) comprises 8
metabolites of which 7 are knowns, namely cysteine, uridine and
five hormones/neurotransmitters: cortisol, 3-methoxy-4-hydroxy
phenylglycol (MHPG), dopamine, noradrenaline and normeta-
nephrine. In general, the AD related metabolic changes are light
to moderate, e.g. increase by up to ,40% in the case of cortisol
(figure 2) or increase by 20–25% primarily in light AD patients for
cysteine (figure 3). Further examples are uridine and MHPG
which both are slightly decreased by ,10–20% in AD patients
compared to healthy subjects. In the case of cortisol the degree of
change seems to be related to the severity of AD, i.e. alterations
compared to controls are higher in the group of AD patients
exhibiting an MMSE score of 14–22 than in patients with
MMSE.22 (figure 2).
Most metabolite changes were particularly observed in the light
AD groups (table 2). Interestingly, the combination of cysteine
elevation and uridine decrease is best suited for distinguishing
these AD patients from healthy controls (figure 4).
Multivariate statistical analysis of SQ-analytes
P r i n c i p a lc o m p o n e n ta n a l y s i s( P C A )f o ra l l1 3 0s a m p l e sb a s e do n
the 343 SQ-analytes showed partial separation of gender in the score
Figure 1.The metabolite profiling techniques applied to the
analysis of CSF samples.
doi:10.1371/journal.pone.0031501.g001
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samples from males and females exhibit an influence of age and/or
disease on the metabolite profile. In the PCA score plot AD patients,
especially the elder ones, are shifted approximately orthogonal to the
genderrelatedsegregation,i.e.primarilyalongprincipalcomponent1.
Analytes contributing significantly to separation between AD
patients and healthy controls were determined by O-PLS-DA of the
CSF data set (see material and methods). The resulting score plot,
involvingall343SQ-analytesinthecalculation,isshowninfigure5a
where separation between AD patients (MMSE.22) and healthy
controls was observed (cross-validation performed; Q
2=0.23).
The relative contribution to class separation is visualized for the
343analytes inthecorrespondingO-PLS coefficient plot (figure 5b).
The prominent role of cysteine and uridine for discriminating both
groups, a result which was already deduced from univariate
statistics, is confirmed. A similar comparison of the SQ-analyte
profile of patients exhibiting strong AD with those of healthy
subjects by O-PLS-DA leads to an equally good class differentiation
in the score plot (data not shown). Again cortisol was found to be the
most prominent analyte contributing to separation in addition to
dopamine, sorbitol and several unknowns.
Linear modeling of systematic differences in age, gender
and disease status
Systematic differences such as age, gender and center between
AD patients and healthy controls are inherently present in this
data set (table 1),Therefore, systematic age- and gender-related
effects were corrected by applying linear modeling employing the
relative concentrations (ratios) of all 343 SQ-analytes (see material
and methods for details). In addition to metabolite profiling data,
Table 2. Number of semi-quantitative analytes significantly altered in patients diagnosed with Alzheimer’s disease obtained from
t-test analysis in dependency of gender and significance threshold p (in grey: number of significant changes equal or below
expected false-positive rate).
significance threshold p Females AD MMSE.22 vs. controls AD MMSE 14–22 vs. controls AD all vs. controls
,0.05 All Centers 33 23 29
Core Centers only 20 15 17
,0.01 All Centers 94 1 3
Core Centers only 30 3
significance threshold p Males ADMMSE.22vs. controls ADMMSE 14–22vs. controls ADallvs. controls
,0.05 All Centers 24 21 27
Core Centers only 13 19 13
,0.01 All Centers 46 1 1
Core Centers only 1 6 4
doi:10.1371/journal.pone.0031501.t002
Figure 2.Increase of cortisol concentration observed for AD patients compared to healthy controls.
doi:10.1371/journal.pone.0031501.g002
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included as far as available; however center correction was not
reasonable in view of the limited availability of protein data in this
study. The result of the calculation for all centers with respect to
the influencing factors age, gender and disease status (light; strong
AD) is given in figure 6. The relative changes and significance level
for the 343 SQ metabolites and the proteins Tau, p-Tau 181 and
amyloid beta 42 are shown. The most significant metabolic effects
Figure 3.Increase of relative cysteine levels observed for AD patients compared to healthy controls: most prominent changes
detected in AD patients with MMSE 22.
doi:10.1371/journal.pone.0031501.g003
Figure 4. CSF cysteine and uridine levels of patients (females and males) exhibiting light AD (MMSE.22) compared to healthy
controls: ,75% of all samples can be correctly assigned to the respective patient group by using relative ratios for both metabolites.
doi:10.1371/journal.pone.0031501.g004
Metabolite Profiling of Alzheimer’s Disease CSF
PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e31501are related to sex (blue) and age (green): increased levels of
testosterone and, to a lesser extent, elevated levels of 1,5-
anhydrosorbitol, phenylalanine, valine, choline, carnitine and uric
acids in males, and increased levels of uric acid and several
unknowns with respect to age. The most significant disease related
effects pertain to the proteins Tau/p-Tau (increase) and amyloid
beta42 (decrease) as well as several analytes identified by
metabolite profiling, particularly cysteine, several unknowns,
cortisol and ornithine, including minor components arginine and
citrulline, most of which are best correlated with light AD.
Almost 50% of healthy control samples from males originated
only from one center which did not contribute any AD sample to
the study. On the other hand there was also one center providing
only AD samples and no controls. To account for center effects
due to providing either no control or no AD samples a similar
calculation was done employing only the data from the three core
centers which provided samples from both, healthy controls and
AD patients (result not shown). This calculation included only
metabolite profiling data and not protein data because protein
data was insufficient for this sample subset (5 female and 2 male
values). The most prominent disease effects on metabolites were
identified for cysteine (increase), taurine (increase) and for uridine,
mannose and several unknowns which all decreased.
Potential markers from metabolite profiling by
discriminant analysis
In order to identify the most promising AD-related parameters
corrected for age- and gender-related effects according to their
univariate performance in linear modeling, the significance levels
for all center calculation (fig. 6) were related to those obtained for
core center results, both for correlation with light AD status and
strong AD status, respectively. Then, the set of analytes exhibiting
sufficient univariate performance, i.e. having p values ,0.1 in the
‘all’ center and ,0.2 in the ‘core’ center models, was selected. In
case of light AD the metabolites fulfilling these criteria were 5
unknown and 11 known analytes, namely cysteine, tyrosine,
phenylalanine, methionine serine, pyruvate, taurine, creatinine,
cortisol, dopamine and uridine. Much less analytes showed
comparably strong correlations with later stages of AD (MMSE
14–22), namely 9 unknowns with two of them also appearing in
the light AD model above, and two knowns, ornithine and cortisol.
The subsequent discriminant analyses focused on light AD
(MMSE.22), i.e. on the 16 analytes selectedafter correctionof age-
and gender-related effects (see above). The rationale for this lies in
the limited number of samples from patients exhibiting strong AD
(MMSE 14–22) and the substantial interest in diagnosing AD
particularly at early stages, combined with the fact that metabolite
alterations were more prominent in the group of light AD patients.
The most powerful metabolite pairs, triplets, quartets and quintets
from the 16 identified metabolites were evaluated from all possible
metabolite combinations by applying multivariate classification
(PLR). The top five metabolite combinations with highest ROC
AUC values are depicted in table 3 for each number of metabolites.
The ROC AUC values are biased upwards by the selection of best
metabolite combinations from the large set of all metabolite
combinations of given dimension. Unbiased ROC AUC perfor-
mance estimates for the biomarker nominations of Table 3 require
ROC analysis of new samples from an additional validation study.
The best metabolite pair (cysteine+uridine) allows AD predic-
tion with e.g. ,75% sensitivity and ,75% specificity. In general,
.80% sensitivity with .80% specificity is observed for quite a few
metabolite combinations, mainly quartets and quintets, e.g. the
quartet uridine, cortisol, cysteine and unknown U096 (figure 7). In
comparison, AUC values between 0.85 to 0.97 are obtained for
single to combinations of all three proteins Tau, P-T and amyloid
beta42. However, the predictive potential might be overestimated
in the case of proteins, as no center corrections could be applied
due to the limited number of cases. That center dependence seems
to exist was concluded from a PCA on total Tau, pTau and
amyloid beta42 for 17 patients with light AD and 19 controls,
where 12 of the controls came from the one center which provided
only control samples. Controls originating from this center
appeared to be more different compared to AD samples than
observed for the controls from the other centers.
Aside from the combinations shown in Table 3 which are
dominated by cysteine, uridine and cortisol, further combinations
Figure 5. Determination of analytes contributing significantly to separation between AD patients and healthy controls by O-PLS-
DA of the CSF data set. (A) OPLS-DA score plot for light AD patients (MMSE.22) vs. controls. (B) OPLS-DA coefficient plot for light AD patients
(MMSE.22) vs. controls. Cysteine and uridine are the most relevant analytes for separating light AD patients (MMSE.22) from healthy subjects.
doi:10.1371/journal.pone.0031501.g005
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dependent on the performance of these three metabolites, e.g. the
quartets cortisol, serine, unknown U528 and either unknown U096
or dopamine with AUC values 0.806 and 0.804, respectively. The
amino acid focused quintet cysteine, serine, phenylalanine and
tyrosine together with uridine has an AUC value of 0.799.
Discussion
Alzheimer’s disease (AD) is characterized by progressive
neurodegeneration – large scale atrophy of brain tissue in many
brain regions. It is evident that different brain structures are
affected differentially during progression starting with hypotha-
lamic structures before progressing to the cortex. It can be
assumed that these changes in neuronal integrity as well as the
underlying pathology lead to changes in brain metabolism which is
reflected in the composition of metabolites in CSF.
In the current study we applied very sensitive and quantitative
analytical tools to detect these changes in brain metabolism. We
show that using metabolite profiling; statistically significant
differences in CSF between AD patients and controls can be
detected. In general these differences are moderate, the increase is
only up to around 40% (for cortisol, see below) and in addition
there is a considerable overlap between the sample groups.
However, the data strongly suggest that chronic neuronal changes
in the brain of AD patients result in changes in brain metabolism
which can be detected in CSF.
It is particular interesting to look into neurotransmitter systems,
sincethesedirectlyreflectactivityandintegrityofneuronal networks.
Acetylcholinesterase inhibitors are currently used in AD therapy
to address cognitive symptoms. As early as in the mid-70s, it had
beenestablished that choline acetyltransferase activity is muchmore
reduced in brain tissue from AD patients than in age-matched
controls – an observation commonly known as cholinergic deficit in
AD [17]. Due to its rather low concentration, a direct confirmation
of resulting lowering of acetylcholine in CSF could be demonstrated
only in the mid-90s [18]. Observed acetylcholine concentrations in
normal patients reach 30610 nM, compared to 864n Mi nA D
patients. Acetylcholine is a highly charged small molecule that was
could not be included in our metabolite panel, therefore we have no
estimate of this difficult to analyze established marker.
However, while cortical cholinergic neurons suffer most
pronounced losses, other types of neurons are progressively
affected as well and this is reflected in changes in the concentration
of norepinephrine (NE) and its major metabolite 3-methoxy-4-
hydroxy phenylglycol (MHPG) as we have observed in our study.
It has been established that up to 80% of the neurons located in
the locus coeruleus are lost in AD [19]. As a result, the
Figure 6. Significance levels and relative changes with respect to influencing factors gender, age and disease status (light AD;
strong AD) are shown. All SQ 343 analytes measured by metabolite profiling, and the proteins TAU, p-TAU 181 and amyloid beta 42 were included
in the linear modeling calculation. In the case of gender-related correlations (blue circles) relative changes .1 indicate increased levels in males
compared to females (logarithmic scale for both axes; relative change for age-related effects are not-to-scale).
doi:10.1371/journal.pone.0031501.g006
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coeruleus neuronal projections in the frontal and temporal cortex
is substantially lowered [20]. It appears that increased NE
concentrations in CSF as we have observed in our study are a
reflection of compensatory effects, connected with higher activities
per neuron and higher secretion into the CSF. Paradoxically, the
majority of studies find different results in CSF – ranging from
unchanged levels to a marked increase of NE or its major
metabolite 3-methoxy-4-hydroxy phenylglycol (MHPG). Loss of
neurons in the locus coeruleus occurs progressively with increasing
age, but older subjects have commonly higher levels of NE in CSF
than young adults. However, NE concentrations in CSF of AD
patients can be much higher than those seen in cognitive normal
elderly patients. It appears that noradrenergic neurons can re-
innervate de-innervated cholinergic brain regions [21]. Moreover,
NE concentrations in CSF due to apparent NE- dependent
compensation can be induced by factors such as insulin and can
lead to improved mental control and memory recall [22].
Finally, in normal aging, tyrosine hydroxylase and aromatic
acid decarboxylase enzyme activities decrease but monoamine
oxidase activity increases. Therefore, dopamine and its metabolic
product HVA are expected to be lowered in CSF of the elderly,
and AD disease progression should add to the deficit. Indeed, AD
patients have slightly (18–27%) lowered dopamine levels in cortical
tissues and the hippocampus [20,23]. Compensation mechanisms
can increase the activity of the remaining neurons to an extent that
the levels of dopamine or HVA in CSF appear unchanged until
late into the course of the disease [24]. However, slightly lowered
levels are observed with appropriate selection of the patient
population [25]. Our study identifies dopamine as one of the few
catecholamines differentiating AD from controls, which is
consistent with the described observations in literature.
Hyperactivity of the HPA axis and increased cortisol levels in
CSF and serum of AD patients has been described previously in AD
patients in several studies [26,27,28]. Here we confirm these earlier
finding. Interestingly, there is no significant difference between
mean cortisol levels in the light dementia group compared to the
more severe demented patients. Thisargues that cortisol may reflect
early pathological changes in the brain. It has been shown that
cortisol undergoes circadian rhythm and could be also induced by
the stress of the lumbar puncture itself [29]. In our study there was
no systematic bias in the time point of CSF sampling between AD
patients and controls. However it could well be that AD patients are
more responsive to stress than healthy control and this again would
argue for deregulation of the HPA axis.
Uridine is a nucleoside and as such part of RNA. In addition, it
is besides choline and DHA also one of the precursor of
phosphatidylcholine (PC) which is synthesized via the Kennedy
Table 3. Metabolite combinations with highest predictive potentials according to ROC AUC values starting with most promising
metabolite combination (‘‘rank’’) for each combination type (pairs, triplets, quartets, quintets). Multivariate classification was based






































































































































triplets 1 x x x 0.825
2 x x x 0.816
3xx x 0.813
4x xx 0.806
5 x x X 0.805
quartets 1 x x x x 0.836
2 x x x x 0.833
3 x x x x 0.832
4 x x x x 0.831
5 x x x X 0.831
quintets 1 x x x x x 0.845
2 x x x x x 0.843
3 x x x x x 0.841
4 x x x x x 0.840
5xxx x x 0.839
doi:10.1371/journal.pone.0031501.t003
Metabolite Profiling of Alzheimer’s Disease CSF
PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e31501cycle. PC is the major component of cellular membranes. It has
been reported that dietary supplementation of these precursors
increase the synthesis of phosphatides in the brain, the number of
synapse and also promotes the formation of dendritic spines in the
hippocampus (for review see [30]). The observed reduction of
uridine in the CSF of AD patients could reflect the reduced
synaptic plasticity and neuronal deficits.
There have been many reports that metabolic dysfunction is
linked to the pathology AD. The incidence of diabetes is increased
in AD and it has been hypothesized that Insulin resistance in the
brain contributes to AD pathology (for review see [31]).
Interestingly in our data set we do not see any significant
differences in glucose in CSF of AD patients or metabolites linked
to insulin resistance. It might well be that these proposed
metabolic abnormalities are not reflected in CSF.
Homocysteine as well as cysteine have been reported to be
elevated in plasma and serum of AD patients [32]. Many studies
have shown that increased homocysteine is associated with an
increased risk of cognitive impairment and dementia, however this
is still discussed controversially (for review see [33]). Homocysteine
levels are not changed in the CSF of AD patients [34]. However,
in the present study we detect a significant increase of cysteine in
CSF of AD patients. Homocysteine can be metabolized to cysteine
and the observed increased levels of cysteine could reflect a
misbalance in the homocysteine metabolic system. Further studies
in possibly larger patient cohorts are needed to confirm these
findings. One clinical study has shown that lowering of
homocysteine in plasma by Vitamin B12 slows the rate of brain
atrophy, however without effect on cognitive parameters [35].
These data argue again that the increase in cysteine levels in AD
patients as observed in our study is a marker of neurodegeneration
in the brain of AD patients.
Our study complements efforts to detect changes in CSF protein
composition caused by the neurodegenerative alterations. Indeed,
there have been numerous studies (reviewed in [36] [37] using
novel proteomics approaches that include not only unbiased
analysis of CSF using protein separation techniques and mass
spectroscopy, but also targeted approaches with multiplex panels
of specific analytes. While these studies have found a number of
candidate combinations that could improve on the ‘‘core’’ protein
biomarkers phospho-tau and amyloid beta 42, none has been
validated enough to be included in clinical practice. Many of the
new protein biomarker candidates seem to reflect late degenerative
mechanisms (gliosis or inflammation).
When compared to the published proteomics literature, our
metabolomics approach has a number of distinct advantages:
protein content of the CSF is highly variable and dominated by a
number of abundant plasma proteins that mask a small
contribution of neurons, the number of proteins to be measured
(.5000 species) is much larger than the potential number of
metabolites (a few hundreds), which has implications on the
dimensionality of the experiment and the multiple testing
corrections that need to be applied, and finally, the exchange of
many small molecules between CSF and other body fluids is
restricted and reflects the unique metabolic situation in the brain.
It should be noted, that the data we present here are by no means
biomarkers to be used in clinical practice. In particular, since the
marker performance even of the best metabolitecombinations is not
exceeding the performance of the known protein markers Abeta 42
and Tau in CSF. Furthermore, statistical tools (metabolite selection,
classification, ROC analysis) were applied to find metabolite
combinations with highest diagnostic performance on the current
datasets. The ROC AUC values should not be regarded directly as
performance estimates because of a selection bias that can be quite
strong especially for -omics datasets with many features (‘‘trap of
overfitting’’). A natural next analysis step would be to test the listed
metabolite combinations on new data to get real estimates of their
performance. In any case, the data set has shown that metabolite
profilingtechnology canbe applied to analyze the signature of brain
metabolism in humans during chronic disease and that changes can
be detected reflecting chronic disease processes in the brain such as
Alzheimer’s disease pathology.
Figure 7. Receiver operating characteristics (ROC) curves with AUC values for best analyte pair (top left), triplet (top right), quartet
(bottom left) and quintet (bottom right). Sensitivity (true positive rate) and 1 – specificity (false positive rate) relate to correct prediction of AD
(MMSE.22).
doi:10.1371/journal.pone.0031501.g007
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